iCellate is a Swedish life science company founded in 2011 with its laboratory and office located in Stockholm. iCellate develops cancer diagnostic services across the cancer lifecycle, from hereditary cancer risk (GeneMate®) to early detection, treatment prediction and treatment monitoring (CellMate®). The technologies are based on research from the Karolinska Institute in collaboration with the Karolinska University Hospital.